Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow NEKTAR THERAPEUTICS

Get SEC filing alerts via email and in your feed for NEKTAR THERAPEUTICS

NKTR

NEKTAR THERAPEUTICS

About NEKTAR THERAPEUTICS

Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing immunotherapy medicines. Its pipeline includes drug candidates targeting autoimmune diseases and cancer, utilizing innovative immunomodulatory agents and PEGylation technology. The company advances its research through clinical trials, collaborations, and licensing, aiming to deliver targeted, long-lasting therapies that modulate immune responses for improved patient outcomes worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from NEKTAR THERAPEUTICS

1
1
NEKTAR THERAPEUTICS Nektar Therapeutics Reports $44.9 Million Net Loss and $10.9 Million Revenue in Q1 2026

Via official filing (AI summary) | 28 days ago | 0 comments

2
1
NEKTAR THERAPEUTICS Nektar Therapeutics Reports $164.1 Million Net Loss and 44% Revenue Decline for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
NEKTAR THERAPEUTICS Nektar Therapeutics Reports 51% Revenue Decline in Q3 2025, Focuses on Clinical Pipeline

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
NEKTAR THERAPEUTICS Nektar Therapeutics Reports 52% Revenue Decline and $41.6 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
NEKTAR THERAPEUTICS Nektar Therapeutics Reports $50.9 Million Net Loss and 52% Revenue Decline in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
NEKTAR THERAPEUTICS Nektar Therapeutics Reports $118.96 Million Net Loss and 9% Revenue Increase for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
NEKTAR THERAPEUTICS Nektar Therapeutics Reports Q3 Financial Results, Net Loss Decreases Amid Restructuring Efforts

Via official filing (AI summary) | over 1 year ago | 0 comments